List view / Grid view
24 March 2016 | By Victoria White
Aprecia’s Spritam (levetiracetam) tablets, for oral suspension, are now available in the US as an adjunctive therapy in the treatment of partial onset seizures, myoclonic seizures and primary generalized tonic-clonic seizures.
24 March 2016 | By Victoria White
Xeljanz is the only oral Janus kinase (JAK) inhibitor approved in more than 45 countries around the world for the treatment of moderate to severe RA...
23 March 2016 | By Victoria White
CSL Behring’s Idelvion and Sobi/Biogen’s Alprolix will compete intensely for a share of the haemophilia B market following their expected European approvals...
23 March 2016 | By Victoria White
Polyphor's POL6014 reduces the activity of elastase, an enzyme that destroys lung tissue when it is produced in excess...
23 March 2016 | By CPhI
CPhI Japan, organised by UBM EMEA, will take place at the Big Sight Exhibition Centre, Tokyo, Japan, 20th-22nd April...
23 March 2016 | By Wickham Laboratories Ltd
Wickham Laboratories Ltd will be presenting as part of the biotech track at the 10th annual BioTrinity 2016 conference in London, April 25-27...
The National Institute for Health and Care Excellence (NICE) has issued draft guidance which does not recommend Vertex Pharmaceuticals’ Orkambi (lumacaftor-ivacaftor) for treating cystic fibrosis.
23 March 2016 | By Victoria White
The SOCRATES trial evaluated Brilinta (ticagrelor) versus aspirin for the prevention of major vascular events in patients with an acute ischaemic stroke...
23 March 2016 | By Victoria White
Taltz (ixekizumab) is intended for adult patients who are candidates for systemic therapy, phototherapy or a combination of both...
23 March 2016 | By Victoria White
Patients who added Praluent to their existing treatment regimen significantly reduced the frequency of their apheresis therapy by 75% compared to placebo....
22 March 2016 | By Victoria White
ArQule and Daiichi Sankyo today announced that the independent DMC has determined that the METIV-HCC will continue to its final analysis...
22 March 2016 | By Cherwell Laboratories
New 2016 Redipor® price list available on request...
22 March 2016 | By Victoria White
BUPI is a patent pending lozenge formulation of bupivacaine for pain management in oral mucositis in cancer patients...
22 March 2016 | By Victoria White
The studies will assess the combination of daratumumab and atezolizumab in multiple myeloma and in solid tumour cancer...
22 March 2016 | By Victoria White
Pharmapack Europe, organised by UBM EMEA, held its most successful event yet at the Paris expo Porte De Versailles on the 10th and 11th of February 2016...
